Care plan for children newly diagnosed with acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child age 0 to 18
- This is your first diagnosis of acute lymphoblastic leukemia (ALL)
- You have not had any chemotherapy before
- Your leukemia cell type is FAB L1 or FAB L2
- Your diagnosis is not the ALL L3 (Burkitt) subtype
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Hear when a new Childhood ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.